Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.

about

A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.

P2860

Q41925374-9BBF0B37-4EE3-453D-8926-E895A1AFC382

P2860

Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.

Item

http://www.wikidata.org/entity/Q38511370

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacokinetic drug-drug inte ...... mbination with chemotherapies.

@en

type

Item

label

Pharmacokinetic drug-drug inte ...... mbination with chemotherapies.

@en

prefLabel

Pharmacokinetic drug-drug inte ...... mbination with chemotherapies.

@en

P1476

Pharmacokinetic drug-drug inte ...... mbination with chemotherapies.

@en

P2093

Benjamin Wu

http://www.w3.org/2001/XMLSchema#string

Cheryl A Pickett

http://www.w3.org/2001/XMLSchema#string

Cindy Kitahara

http://www.w3.org/2001/XMLSchema#string

Erick Gamelin

http://www.w3.org/2001/XMLSchema#string

Erik Rasmussen

http://www.w3.org/2001/XMLSchema#string

Jessica Lu

http://www.w3.org/2001/XMLSchema#string

Lei Zhou

http://www.w3.org/2001/XMLSchema#string

Mark Ma

http://www.w3.org/2001/XMLSchema#string

Rebeca Melara

http://www.w3.org/2001/XMLSchema#string

Teresa Wong

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.

Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.

Predicting drug-drug interactions: an FDA perspective

Transporter-mediated drug-drug interactions.

Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

P2888

s00280-015-2748-1

P304

243-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2748-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047552197

http://www.w3.org/2001/XMLSchema#string

P698

26032239

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.

about

P2860

P2860

Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698